Protocol biopsies in renal transplantation: Prognostic value of structural monitoring

Kidney International

Volumn 72, Issue 6, 2007, Pages 690-697

  Seron D ^a   Moreso, F ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Epidemiology and outcomes; Interstitial fibrosis tubular atrophy; Kidney biopsy; Renal transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ATROPHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY STRUCTURE; NEPHROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACUTE DISEASE; BIOPSY; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 34548494343     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002396     Document Type: Review

References (66)

1. Matas AJ, Sibley R, Mauer SM et al. Pre-discharge, post-transplant kidney biopsies does not predict rejection. J Surg Res 1982; 32: 269-274.
2. Burdick JF, Beschorner WE, Smith WJ et al. Characteristics of early routine renal allograft biopsies. Transplantation 1984; 38: 679-683.
3. McWhinnie DL, Thompson JF, Taylor HM et al. Morphometric analysis of cellular infiltration assessed by monoclonal antibody labelling in sequential human renal allograft biopsies. Transplantation 1986; 42: 352-358.
4. Seron D, Diaz Gallo C, Grino JM et al. Characterization of interstitial infiltrate in early renal allograft biopsies in patients with stable renal function. Transplant Proc 1991; 23: 1267-1269.
5. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
6. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
7. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
8. Solez K, Colvin RB, Racusen LC et al. Banff' 05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
9. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Transplantation 1995; 59: 511-514.
10. Nankivell BJ, Borrows RJ, Fung CLS et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-249.
11. Isoniemi HM, Krogerus L, von Willebrand E et al. Histopathological findings in well functioning long term renal allografts. Kidney Int 1992; 41: 155-160.
12. Serón D, Moreso F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310-316.
13. Nankivell BJ, Borrows RJ, Fung CLS et al. The natural history of chronic allograft nephropathy. N Eng J Med 2003; 349: 2326-2333.
14. Marcusen N, Olsen TS, Benediktsson H et al. Reproducibility of the Banff classification of renal allograft pathology. Transplantation 1995; 60: 1083-1089.
15. Furness PN, Taub N. Convergence of European renal transplant pathology assessment procedures. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP project. Kidney Int 2001; 60: 1198-2010.
16. Colvin RB, Cohen AH, Saiontz C et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8: 1930-1941.
17. Gough J, Rush D, Jeffery J et al. Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrol Dial Transplant 2002; 17: 1081-1084.
18. Veronese FV, Manfro RC, Roman FR et al. Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 2005; 19: 518-521.
19. Legendre C, Thervet E, Skhiri H et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506-1509.
20. Gloor JM, Cohen AJ, Lager DJ et al. Subclinical rejection in tacrolimus treated renal transplant recipients. Transplantation 2002; 72: 1965-1968.
21. Moreso F, Seron D, Carrera M et al. Baseline inmunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78: 1064-1068.
22. Moreso F, Ibernon M, Goma M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747-752.
23. Mengel M, Gwinner W, Schwarz A et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7: 356-365.
24. Choi BS, Shin MJ, Sjin SJ et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5: 1354-1360.
25. Roberts ISD, Reddy S, Russell C et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004; 77: 1194-1198.
26. Sholten EM, Rowshani A, Cremers S et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial protocol biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17: 881-888.
27. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046-1052.
28. Cosio FG, Grande JP, Wadei H et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
29. Rush DN, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129-2134.
30. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 9: 2006-2012.
31. Seron D, Moreso F, Fulladosa X et al. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727-733.
32. Fulladosa X, Moreso F, Torras J et al. Structural and functional correlations in stable renal allografts. Am J Kidney Dis 2003; 41: 1065-1073.
33. Birk PE, Stannard KM, Konrad HB et al. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant 2004; 8: 29-38.
34. Bosmans JL, Woestenburg A, Ysebaert DK et al. Fibrous intimal thickening at implantation as a risk factor for the outcome of cadaveric renal allografts. Transplantation 2000; 69: 2388-2394.
35. Schwarz A, Mengel M, Gwinner W et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005; 67: 341-348.
36. Dimény E, Wahlberg J, Larsson E, Fellström B. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995; 9: 79-84.
37. Yilmaz S, Tomlanovich S, Mathew T et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end-point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773-779.
38. Nankivell BJ, Fenton-Lee CA, Kuypers DRJ et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523.
39. Seron D, Moreso F, Ramon JM et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 1849-1855.
40. Melk A, Schmidt BM, Vongwiwatana A et al. Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidneys. Am J Transplant 2005; 5: 1375-1382.
41. Mengel M, Bogers J, Bosmans JL et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005; 5: 1050-1056.
42. Haas M, Montgomery RA, Segev DL et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2006; 6: 1-10.
43. Cyclosporine A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary result of a European Multicenter trial. Lancet 1982; 2: 57-60.
44. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809-815.
45. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
46. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
47. Hariharan S, McBride MA, Cohen EP. Evolution of endpoint for renal transplant outcome. Am J Transplant 2003; 3: 933-941.
48. Hariharan S, Kasiske B, Matas A et al. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004; 4: 1179-1183.
49. Lachenbruch PA, Rosenberg AS, Bonvini EE et al. Biomarkers and surrogate end-points in renal transplantation: present status and considerations for clinical trial design. Am J Transplant 2004; 4: 451-457.
50. The Heart Outcomes Prevention Evaluation (HOPE) 2 investigators. Homocysteine lowering with acid folic and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
51. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961.
52. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a cyclosporine-based regimen results in better renal allograft survival and renal function at forty eight months after transplantation. Transpl Int 2005; 18: 22-28.
53. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J transplant 2003; 3: 1560-1565.
54. Kasiske BL. Endpoint or turning point? Am J Transplant 2003; 3: 1463-1464.
55. Solez K, Vincenti F, Filo RS. Histopathological findings from 2 year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998; 66: 1736-1740.
56. Flechner SM, Kurlan SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785.
57. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
58. Nicholson ML, McCulloch TA, Harper SJ et al. Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 1996; 83: 1082-1085.
59. Nicholson ML, Bailey E, Williams S et al. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999; 68: 236-241.
60. Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of sirius red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 1662-1668.
61. Pape L, Henne T, Offner G et al. Computer-assisted quantification of fibrosis in chronic allograft nephropathy by picrosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003; 76: 955-958.
62. Rowshani AT, Scholten EM, Bemelman F et al. No difference in degree of interstitial sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006; 17: 305-312.
63. Bosmans JL, Holvoet P, Dauwe EH et al. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int 2001; 59: 2346-2356.
64. Azevedo F, Alperovich G, Moreso F et al. Glomerular size in early protocol biopsies is associated with graft outcome. Am J Transplant 2005; 5: 2877-2882.
65. Moreso F, Lopez M, Vallejos A et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001; 1: 82-88.
66. Lopes JA, Moreso F, Riera L et al. Evaluation of pre-implantation kidney biopsies: comparison of Banff criteria to a morphometric approach. Kidney Int 2005; 67: 1595-1600.